Answer
It is licensed for certain ER-positive, HER2-negative locally advanced or metastatic breast cancers with an activating ESR1 mutation after specified previous endocrine treatment.
Sources for this answer
- Korserdu (elacestrant) 86mg film-coated tabletsemc · SmPC Current selected SmPC · Version 3